Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.45 |
| ▸ | PIK3CD | O00329 | 9/20 | 0.43 |
| ▸ | PIK3R1 | P27986 | 7/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1664018 | 0.84 | ESR1 (0.49) | SMN1; SMN2ESR1ESR2RAB9ACYP1A2 | |
| SCHEMBL15816896 | 0.80 | PIK3CD (0.48) | HRH3KCNH2PIK3CDPIK3R1PIK3CG | |
| SCHEMBL15816895 | 0.80 | PIK3CD (0.48) | HRH3KCNH2PIK3CDPIK3R1PIK3CG | |
| SCHEMBL451012 | 0.78 | HRH3 (0.47) | HRH3KCNH2PIK3CDPIK3R1PIK3R2 | |
| SCHEMBL1663939 | 0.77 | ESR1 (0.49) | SMN1; SMN2ESR1ESR2TP53MAPT | |
| SCHEMBL1553986 | 0.77 | HRH3 (0.48) | HRH3KCNH2PIK3CDPIK3R1PIK3R2 | |
| SCHEMBL20061283 | 0.76 | PIK3CD (0.63) | PIK3CDPIK3R1PIK3CG | |
| SCHEMBL15812841 | 0.75 | PIK3CD (0.51) | PIK3CDPIK3R1PIK3R2PIK3CG | |
| SCHEMBL14176447 | 0.75 | ESR1 (0.52) | SMN1; SMN2ESR1ESR2HRH3KCNH2 | |
| SCHEMBL449089 | 0.74 | HRH3 (0.40) | SMN1; SMN2HRH3KCNH2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2305652-A2 | Trisubstituted quinazolinone derivatives as vanilloid antagonists | Novartis AG (CH) | 2011-04-06 | — | — | EP | disclosed |
| US-20090082365-A1 | Trisubstituted Quinazolinone Derivatives as Vanilloid Antagonists | NOVARTIS AG | 2009-03-26 | — | — | US | disclosed |
| EP-1963283-A2 | TRISUBSTITUTED QUINAZOLINONE DERIVATIVES AS VANILLOID ANTAGONISTS | Novartis AG (CH) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007065662-A2 | TRISUBSTITUTED QUINAZOLINONE DERIVATIVES AS VANILLOID ANTAGONISTS | NOVARTIS AG (CH) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082365-A1 | Trisubstituted Quinazolinone Derivatives as Vanilloid Antagonists | TRPV1, TRPV3, TRPV5 | SMN1; SMN2 4016/4885ESR1 1321/4885ESR2 2159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.